TY  - JOUR
AU  - Koh, Gou Young
AU  - Augustin, Hellmut G
AU  - Campochiaro, Peter A
TI  - Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye.
JO  - Trends in molecular medicine
VL  - 28
IS  - 5
SN  - 1471-4914
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2022-00705
SP  - 347-349
PY  - 2022
N1  - DKFZ-ZMBH Alliance / 2022 May;28(5):347-349
AB  - Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
LB  - PUB:(DE-HGF)16
C6  - pmid:35396185
DO  - DOI:10.1016/j.molmed.2022.03.004
UR  - https://inrepo02.dkfz.de/record/179491
ER  -